Should I buy or sell Context Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CNTX shares. View CNTX analyst ratings or view top-rated stocks .

What is Context Therapeutics' stock price target for 2024?

2 brokerages have issued 1 year price targets for Context Therapeutics' stock. Their CNTX share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 192.0% from the stock's current price. View analysts price targets for CNTX or view top-rated stocks among Wall Street analysts .

How have CNTX shares performed in 2024?

Context Therapeutics' stock was trading at $1.13 at the beginning of the year. Since then, CNTX stock has increased by 21.2% and is now trading at $1.37. View the best growth stocks for 2024 here .

Are investors shorting Context Therapeutics?

Context Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 11,200 shares, a decline of 34.1% from the March 15th total of 17,000 shares. Based on an average daily trading volume, of 51,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the company's stock are short sold. View Context Therapeutics' Short Interest .

When is Context Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our CNTX earnings forecast .

How were Context Therapeutics' earnings last quarter?

Context Therapeutics Inc. (NASDAQ:CNTX) announced its quarterly earnings data on Thursday, March, 21st. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.07.

When did Context Therapeutics IPO?

Context Therapeutics (CNTX) raised $25 million in an IPO on Wednesday, October 20th 2021. The company issued 5,000,000 shares at $5.00 per share.

How do I buy shares of Context Therapeutics?

Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:CNTX

Context Therapeutics (CNTX) Stock Price, News & Analysis

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)

Free CNTX Stock Alerts

$1.37

-0.02 (-1.44%)

(As of 04/18/2024 ET)

Compare

Today's Range: $1.37
▼
$1.50
50-Day Range: $1.02
▼
$1.52
52-Week Range: $0.47
▼
$1.69

Volume: 45,929 shs
Average Volume: 53,663 shs
Market Capitalization: N/A

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $4.00

Get Context Therapeutics alerts:

Context Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 192.0% Upside
$4.00 Price Target
Short Interest: Healthy
0.08% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: Growing
From ($1.38) to ($0.71) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.69 out of 5 stars

3.5

Analyst's Opinion

Consensus Rating
Context Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Context Therapeutics has only been the subject of 1 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
0.08% of the float of Context Therapeutics has been sold short.
Short Interest Ratio / Days to Cover
Context Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Context Therapeutics has recently decreased by 34.12%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Context Therapeutics does not currently pay a dividend.
Dividend Growth
Context Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for CNTX.

0.6

News and Social Media Coverage

Search Interest
5 people have searched for CNTX on MarketBeat in the last 30 days. This is an increase of 67% compared to the previous 30 days.

0.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Context Therapeutics insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 6.66% of the stock of Context Therapeutics is held by insiders.
Percentage Held by Institutions
Only 14.03% of the stock of Context Therapeutics is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Context Therapeutics are expected to grow in the coming year, from ($1.38) to ($0.71) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Context Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Context Therapeutics is -0.91, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Context Therapeutics has a P/B Ratio of 1.85. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad DTI

Biden’s $374B Giveaway Into This Sector

Biden’s Climate Bill Could Send Your Retirement Accounts Soaring – Or Diving See what this $374B giveaway could mean for your retirement right here

Click here for the full story

About Context Therapeutics Stock (NASDAQ:CNTX)

Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors in the United States. It develops CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.

CNTX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CNTX Stock News Headlines

April 3, 2024 | msn.com

Context Therapeutics Takes Bold Step with IND Submission for Groundbreaking Cancer Therapy

April 2, 2024 | cnn.com

Context Therapeutics, Inc.

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

April 1, 2024 | markets.businessinsider.com

Context Therapeutics Submits IND For CTIM-76

April 1, 2024 | globenewswire.com

Context Therapeutics Submits IND Application to Evaluate CTIM-76 in Claudin 6-Positive Cancers

March 22, 2024 | markets.businessinsider.com

Buy Rating Justified by Advances in T Cell Engagers and Context Therapeutics’ Strategic Drug Positioning

March 21, 2024 | investorplace.com

CNTX Stock Earnings: Context Therapeutics Misses EPS for Q4 2023

March 21, 2024 | finanznachrichten.de

Context Therapeutics Inc.: Context Therapeutics Reports Full Year 2023 Operating and Financial Results

April 18, 2024 | Gold Safe Exchange (Ad)

The “Perfect Storm” for Gold

Gold has already reached all-time highs, and experts believe it's not slowing down any time soon. In fact, some analysts predict a $7,000 price tag by 2025.

March 21, 2024 | globenewswire.com

Context Therapeutics Reports Full Year 2023 Operating and Financial Results

December 27, 2023 | benzinga.com

Context Therapeutics Stock (NASDAQ:CNTX), Short Interest Report

December 27, 2023 | benzinga.com

Context Therapeutics Stock (NASDAQ:CNTX) Dividends: History, Yield and Dates

November 28, 2023 | msn.com

Context Therapeutics (CNTX) Price Target Increased by 21.31% to 3.77

November 10, 2023 | finanznachrichten.de

Context Therapeutics Inc.: Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

November 10, 2023 | proactiveinvestors.com

Context Therapeutics prepares for CTIM-76 filing, ends 3Q with enough cash to last through late 2024

November 9, 2023 | msn.com

Context Therapeutics GAAP EPS of -$0.37 misses by $0.06

November 9, 2023 | finance.yahoo.com

Context Therapeutics Reports Third Quarter 2023 Operating and Financial Results

November 2, 2023 | msn.com

HC Wainwright & Co. Upgrades Context Therapeutics (CNTX)

November 1, 2023 | benzinga.com

Context Therapeutics Stock (NASDAQ:CNTX), Analyst Ratings, Price Targets, Predictions

October 31, 2023 | proactiveinvestors.com

Context Therapeutics reveals ‘encouraging’ preclinical data for CTIM-76 tumor treatment

October 31, 2023 | finance.yahoo.com

Context Therapeutics Announces Preclinical Data Demonstrating Differentiated and Active Profile of its Claudin 6-Targeted Bispecific Antibody CTIM-76

October 8, 2023 | finance.yahoo.com

Context Therapeutics Inc. (CNTX)

October 5, 2023 | msn.com

Context Therapeutics (CNTX) Price Target Increased by 45.24% to 3.11

September 28, 2023 | markets.businessinsider.com

Context Therapeutics’ Promising CLDN6 Targeting Asset CTIM-76 and Potential Market Valuation Opportunities: An Analyst’s Buy Rating Perspective

September 27, 2023 | proactiveinvestors.com

Context Therapeutics says CTIM-76 abstract accepted for presentation at SITC annual meeting

September 27, 2023 | finance.yahoo.com

Context Therapeutics Announces Acceptance of Abstract to be Presented at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting

September 11, 2023 | msn.com

Maxim Group Initiates Coverage of Context Therapeutics (CNTX) with Buy Recommendation

See More Headlines

Receive CNTX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Context Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 3/21/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:CNTX
CUSIP: N/A
CIK: 1842952
Web: www.contexttherapeutics.com
Phone: 267-225-7416
Fax: N/A
Employees: 5
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $4.00
High Stock Price Target: $4.00
Low Stock Price Target: $4.00
Potential Upside/Downside: +179.7%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.50)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-23,960,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -115.50%
Return on Assets: -97.04%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.83
Quick Ratio: 3.83

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $0.74 per share
Price / Book: 1.93

Miscellaneous

Outstanding Shares: N/A
Free Float: N/A
Market Cap: N/A
Optionable: Not Optionable
Beta: 2.17

The 10 Best AI Stocks to Own in 2024

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Key Executives

Mr. Martin A. Lehr (Age 40)
Co-Founder, President, CEO & Director
Comp: $725.25k
Ms. Jennifer Minai-Azary (Age 46)
CFO & Treasurer
Comp: $533.65k
Mr. Alex C. Levit Esq. (Age 45)
Chief Legal Officer & Corporate Secretary
Comp: $512.1k
Mr. Christopher Beck M.B.A.
Senior Vice President of Operations

Key Competitors

View All Competitors

Institutional Ownership

Opaleye Management Inc.
Bought 975,000 shares on 2/15/2024
Ownership: 6.107%

View All Institutional Transactions

CNTX Stock Analysis - Frequently Asked Questions

Should I buy or sell Context Therapeutics stock right now?: 2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Context Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" CNTX shares.
View CNTX analyst ratings or view top-rated stocks.
What is Context Therapeutics' stock price target for 2024?: 2 brokerages have issued 1 year price targets for Context Therapeutics' stock. Their CNTX share price targets range from $4.00 to $4.00. On average, they expect the company's share price to reach $4.00 in the next twelve months. This suggests a possible upside of 192.0% from the stock's current price.
View analysts price targets for CNTX or view top-rated stocks among Wall Street analysts.
How have CNTX shares performed in 2024?: Context Therapeutics' stock was trading at $1.13 at the beginning of the year. Since then, CNTX stock has increased by 21.2% and is now trading at $1.37.
View the best growth stocks for 2024 here.
Are investors shorting Context Therapeutics?: Context Therapeutics saw a decline in short interest in the month of March. As of March 31st, there was short interest totaling 11,200 shares, a decline of 34.1% from the March 15th total of 17,000 shares. Based on an average daily trading volume, of 51,100 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.1% of the company's stock are short sold.
View Context Therapeutics' Short Interest.

When is Context Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our CNTX earnings forecast.
How were Context Therapeutics' earnings last quarter?: Context Therapeutics Inc. (NASDAQ:CNTX) announced its quarterly earnings data on Thursday, March, 21st. The company reported ($0.42) earnings per share for the quarter, missing the consensus estimate of ($0.35) by $0.07.
When did Context Therapeutics IPO?: Context Therapeutics (CNTX) raised $25 million in an IPO on Wednesday, October 20th 2021. The company issued 5,000,000 shares at $5.00 per share.
How do I buy shares of Context Therapeutics?: Shares of CNTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CNTX) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial